Which agent is the most suitable for a patient experiencing infertility due to anovulation?

Clomiphene is the most suitable agent for a patient experiencing infertility due to anovulation because it functions as a selective estrogen receptor modulator (SERM) that stimulates the release of gonadotropins—follicle-stimulating hormone (FSH) and luteinizing hormone (LH)—from the pituitary gland. This stimulation aids in the induction of ovulation, making it a first-line treatment option for women who are anovulatory due to conditions like polycystic ovary syndrome (PCOS).

The mechanism of clomiphene involves blocking estrogen receptors in the hypothalamus, which leads to an increase in the secretion of gonadotropin-releasing hormone (GnRH). This, in turn, promotes ovulation by encouraging the growth of ovarian follicles.

Other agents listed, such as ospemifene and raloxifene, are SERMs but are primarily used for postmenopausal symptoms and osteoporosis prevention, and not for inducing ovulation. Ulipristal, a selective progesterone receptor modulator, is used mainly as an emergency contraceptive and does not have a role in the treatment of anovulation for infertility. Thus, clomiphene is specifically indicated for treating an